Sugi Predict

Sugi Predict / Compounds / SCHEMBL1243375

SCHEMBL1243375

SCHEMBL1243375

Oc1ccc2ccnc(Cl)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 8/20 0.47
▸ LMNA P02545 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ APEX1 P27695 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ PMP22 Q01453 1/20 0.47
▸ CYP17A1 P05093 7/20 0.45
▸ CYP11B1 P15538 7/20 0.45
▸ CYP11B2 P19099 7/20 0.45
▸ PARG Q86W56 1/20 0.42
▸ ESR1 P03372 2/20 0.42
▸ ESR2 Q92731 2/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ CASP1 P29466 1/20 0.41
▸ CASP7 P55210 1/20 0.41
▸ HIPK2 Q9H2X6 1/20 0.40
▸ ESRRB O95718 1/20 0.39
▸ ESRRA P11474 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30738206 0.84 MAPT (0.43) CYP3A4LMNAMAPTAPEX1MAPK1
SCHEMBL1204569 0.84 MAPT (0.43) CYP3A4LMNAMAPTAPEX1MAPK1
SCHEMBL29786977 0.79 LMNA (0.50) CYP3A4LMNAMAPTAPEX1MAPK1
SCHEMBL1317870 0.79 LMNA (0.50) CYP3A4LMNAMAPTAPEX1MAPK1
SCHEMBL25368878 0.76 MAPT (0.47) CYP3A4LMNAMAPTAPEX1MAPK1
SCHEMBL664591 0.76 LMNA (0.47) CYP3A4LMNAMAPTAPEX1MAPK1
SCHEMBL30497190 0.76 LMNA (0.47) CYP3A4LMNAMAPTAPEX1MAPK1
SCHEMBL29439750 0.76 PLAU (0.51) CYP3A4LMNAMAPTAPEX1MAPK1
SCHEMBL13334192 0.76 LMNA (0.47) CYP3A4LMNAMAPTAPEX1MAPK1
SCHEMBL1315422 0.76 MAPT (0.47) CYP3A4LMNAMAPTAPEX1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129028-A1 COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR Opna Bio SA (CH) 2025-04-24 — — US disclosed
EP-4469036-A2 COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR Opna Bio SA (CH) 2024-12-04 — — EP disclosed
US-20230339960-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER (US) 2023-10-26 — — US disclosed
WO-2023147063-A2 COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR Opna Bio SA (CH) 2023-08-03 — — WO disclosed
WO-2023147063-A2 COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR Opna Bio SA (CH) 2023-08-03 — — WO disclosed
US-11702424-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2023-07-18 — — US disclosed
EP-3536685-B1 BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS PFIZER (US) 2022-02-16 — — EP disclosed
US-20200377511-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds PFIZER INC. (US) 2020-12-03 — — US disclosed
US-10793579-B2 Bicyclic-fused heteroaryl or aryl compounds PFIZER INC. (US) 2020-10-06 — — US disclosed
EP-3536685-A1 BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS Pfizer Inc (US) 2019-09-11 — — EP disclosed
EP-1913016-B1 MACROCYCLIC PEPTIDES AS HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2013-01-16 — — EP disclosed
US-8278322-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2012-10-02 — — US disclosed
US-8278322-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2012-10-02 — — US disclosed
US-8278322-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2012-10-02 — — US disclosed
US-20110028494-A1 HCV NS3 Protease Inhibitors MERCK SHARP & DOHME LLC 2011-02-03 — — US disclosed
US-20110028494-A1 HCV NS3 Protease Inhibitors MERCK SHARP & DOHME LLC 2011-02-03 — — US disclosed
US-20110028494-A1 HCV NS3 Protease Inhibitors MERCK SHARP & DOHME LLC 2011-02-03 — — US disclosed
EP-1913016-A1 MACROCYCLIC PEPTIDES AS HCV NS3 PROTEASE INHIBITORS Merck & Co., Inc. (US) 2008-04-23 — — EP disclosed
WO-2007016441-A1 MACROCYCLIC PEPTIDES AS HCV NS3 PROTEASE INHIBITORS MERCK & CO., INC. (US) 2007-02-08 — — WO disclosed
WO-2007016441-A1 MACROCYCLIC PEPTIDES AS HCV NS3 PROTEASE INHIBITORS MERCK & CO., INC. (US) 2007-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129028-A1 COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR YAP1, YES1, LATS1 CYP3A4 3552/4885LMNA 2251/4885MAPT 233/4885
US-20200377511-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds UGT2B7, CYP3A43, CYP3A4 CYP3A4 3/4885LMNA 1045/4885MAPT 22/4885
US-10793579-B2 Bicyclic-fused heteroaryl or aryl compounds UGT2B7, CYP3A43, CYP3A4 CYP3A4 3/4885LMNA 1045/4885MAPT 22/4885
US-20230339960-A1 Bicyclic-Fused Heteroaryl or Aryl Compounds TTR, TYR, ABL1 CYP3A4 484/4885LMNA 2082/4885MAPT 9/4885
US-20110028494-A1 HCV NS3 Protease Inhibitors HAVCR2, GTF3C3, CTSC CYP3A4 154/4885LMNA 3730/4885MAPT 4330/4885
US-11702424-B2 Bicyclic-fused heteroaryl or aryl compounds UGT2B7, CYP3A43, CYP3A4 CYP3A4 3/4885LMNA 1045/4885MAPT 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.